Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has received US Food and Drug Administration (USFDA) approval for its Supplemental New Drug Application (sNDA) for XiminoTM (Minocycline HCl) extended-release capsules 45 mg, 90 mg and 135 mg.

Ximino extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. This approval further strengthens the company’s branded dermatology portfolio in the US. It expects Ximino extended-release capsules to be available for patients during the fourth quarter of 2015.

Sun Pharmaceutical Industries is a leading Indian pharmaceutical company engaged in developing, manufacturing and marketing formulations and APIs. Its business is broadly categorized in four segments - India Branded Generics, US Formulations, International Generics or RoW business and APIs.